Method, system and apparatus for control of pancreatic beta cell function to improve glucose homeostasis and insulin production

• US 8,903,501 B2
• Filed: 03/30/2012
• Issued: 12/02/2014
• Est. Priority Date: 12/17/2010
• Status: Expired due to Fees

• Current Assignee: Neural Diabetes, LLC
• Original Assignee: Neural Diabetes
• Inventors: Perryman, Laura Tyler
• Primary Examiner(s): Stice, Paula J
• Application Number:
  US13/436,293
• Publication Number:
  US 20120303098A1
• Time in Patent Office: 977 Days
• Field of Search: 607/62, 607116-118
• US Class Current: 607/62
• CPC Class Codes: A61N 1/36057 adapted for stimulating afferent nerves
• CPC Class Codes: A61N 1/36121 Production of neurotransmitters; Modulation of genes expression
• CPC Class Codes: A61N 1/372 Arrangements in connection with the implantation of stimulators
• CPC Class Codes: A61P 5/22 for decreasing, blocking or antagonising the activity of calcitonin

Abstract

The present invention provides methods, systems and apparatuses for effecting excitation or inhibition of small sensory nerve fibers, such as C-afferent fibers, by electrical stimulation of nerves innervating the pancreas in diabetic subjects. In an aspect the methods are directed to effecting insulin production and for the treatment of diabetes. This invention includes a closed or open loop feedback control system in which biomarker levels are monitored in order to direct electrical stimulation. An implantable or external neural stimulation device is also provided.

Claims

1. A method for treating a metabolic disease or disorder in a human subject suffering from said metabolic disease or disorder by inhibiting secretion of calcitonin gene-related peptide (CGRP) from one or more C-afferent sensory nerve fibers, comprising:

applying, via a pulse generator in operable communication with an implantable lead, an electrical impulse to one or more C-afferent sensory nerve fibers innervating pancreatic beta cells in the subject, the electrical impulse configured to have a frequency ranging from 60 to 10,000 Hz and further configured to inhibit the secretion of CGRP from the one or more C-afferent sensory nerve fibers to treat the metabolic disease/disorder.

2. The method of claim 1 wherein the applying step is carried out by applying the electrical impulse using one or more electrodes or pairs thereof.

3. The method of claim 2 in which said one or more electrodes or pairs thereof are contained in an implantable or percutaneous device, the method further comprising positioning the implantable or percutaneous device in said subject at a target site proximal to nerve tissue to be stimulated, wherein the target site includes one or more of the following:

proximal to epidural spinal cord column at any vertebral segment from T7 to L1, dorsal root or dorsal root entry zone at any vertebral segments from T7 to L1, spinal nerve bundles leaving at any vertebral segments from T7 to L1, dorsal root ganglia bundles leaving at any vertebral segments from T7 to L1, peripheral nerves innervating endocrine pancreas beta cells, abdominal nerves or their cutaneous branches, a surface of endocrine pancreas, or combinations thereof.

4. The method of claim 3 in which said one or more electrodes or pairs thereof are placed ipsilaterally or bilaterally.

5. The method of claim 2 wherein the applying step is carried out via two or more electrode pairs contained in one or more implantable leads or percutaneous devices and said applying step is carried out simultaneously or sequentially.

6. The method of claim 2 further comprising wirelessly transmitting an input signal from a location outside of a body of the subject to an implantable or percutaneous device comprising the one or more electrodes or pairs thereof and converting the input signal into the electrical impulse at a target site within the body of the subject.

7. The method of claim 6 wherein the input signal comprises energy to provide power to the implantable or percutaneous device.

8. The method of claim 1 wherein the electrical impulse has a pulse width from about 450 to 1000 microseconds and a power amplitude from 0.2 to 14 Volts (V) or 0.1 to 20 milliamps (mA).

9. The method of claim 1 wherein said metabolic disease or disorder comprises diabetes mellitus.

10. The method of claim 1 wherein said metabolic disease or disorder comprises Type I diabetes.

11. The method of claim 1 wherein said metabolic disease or disorder comprises Type II diabetes.

12. The method of claim 1 wherein said metabolic disease or disorder comprises diabetes insipidus.

13. The method of claim 1 further comprising determining a level of a biomarker in the subject and applying additional electrical impulses to the one or more C-afferent sensory nerves as a function of the level of the biomarker.

14. The method of claim 13 in which said subject effects the step of applying additional electrical impulses.

15. The method of claim 13 in which the step of applying additional electrical impulses is effected automatically.

16. The method of claim 13 in which said biomarker is selected from the group consisting of insulin, glucose, CGRP, abdominal skin blood flow, abdominal skin temperature and abdominal muscle activity.

17. The method of claim 16 in which:

a. said biomarker is insulin and,

i. said subject is a male subject and said level is below about 8.8 μ

IU/mL or said subject is a female subject and said level is below about 8.4 μ

IU/mL; and

the electrical impulse is configured to excite said C-afferent sensory nerve fibers innervating pancreatic beta cells;

or

ii. said subject is a male subject and said level is above about 8.8 μ

IU/mL or said subject is a female subject and said level is above about 8.4 μ

IU/mL; and

the electrical impulse is configured to inhibit said C-afferent sensory nerve fibers innervating pancreatic beta cells;

or,

b. said biomarker is glucose; and

i. said level is above about 120 mg/dL and the electrical impulse is configured to excite said C-afferent sensory nerve fibers innervating pancreatic beta cells;

or

ii. said level is below about 100 mg/dL and the electrical impulse is configured to inhibit said C-afferent sensory nerve fibers innervating pancreatic beta cells.

18. The method of claim 13 in which said biomarker is selected from the group consisting of H1Ac and inflammatory cytokines.

19. A system adapted for treating a metabolic disease or disorder in a human subject suffering form said metabolic disease or disorder by inhibiting secretion of CGRP from one or more C-afferent sensory nerve fibers, comprising:

a power supply configured to generate an electrical impulse having a frequency of 60 Hz to 10,000 Hz; and

an implantable lead configured to apply the electrical impulse configured to stimulate C-afferent sensory nerve fibers innervating pancreatic beta cells in a subject, wherein the electrical impulse is configured to inhibit a secretion of CGRP from said C-afferent sensory nerve fibers.

20. The system of claim 19 wherein the implantable lead is configured for positioning adjacent to or near a dorsal root ganglion, splenic nerve, or dorsal column.

21. The system of claim 19 wherein the power supply is configured to generate the electrical impulse in an open loop format.

22. The system of claim 21 wherein the power supply is configured to generate the electrical impulse at predetermined intervals.

23. The system of claim 21 wherein the power supply is configured to generate the electrical impulse in a manner to maintain hormone levels at a predetermined concentration.

24. The system of claim 21 in which the open loop format comprises alerting the subject to a change in glucose homeostasis.

25. The system of claim 21 further comprising a sensor for detecting a biomarker in the subject and wherein the subject is alerted when the biomarker level achieves a threshold level.

26. The system of claim 25 further comprising a controller coupled to the power supply and configured to compare detected biomarker levels to at least one predetermined range, and the sensor is configured to transmit information about the biomarker level to the controller.

27. The system of claim 25 wherein the controller is further configured to compare the biomarker level to an historic or normative level and adjust the electrical impulse based on the comparison.

28. The system of claim 26 wherein the controller is further configured to initiate adjustments to parameter settings of the electrical impulse.

29. The system of claim 28 wherein the controller is further configured to evaluate the efficacy of the electrical impulse so that the parameter settings can be adjusted.

30. The system of claim 28 wherein the controller is implantable in the subject.

31. The system of claim 21 further comprising a controller for allowing the subject to initiate generation of the electrical impulse.

32. The system of claim 19 wherein the power supply is configured to generate the electrical impulse in a closed loop format.

33. The system of claim 19 wherein the implantable lead further comprises an antenna for receiving incoming signals from an external programmer.

34. The system of claim 33 wherein the power supply is configured to electrically process the incoming signals and produce the electrical impulse sequentially without the aid of a battery.

35. The system of claim 19 wherein the electrical impulse is charge-balanced.

36. The system of claim 19 wherein the electrical impulse is generated automatically.

37. An apparatus adapted for inhibiting secretion of CGRP from one or more C-afferent sensory nerve fibers comprising:

a sensor configured to detect a biomarker level;

a pulse generator configured to produce electrical stimulation as a function of the biomarker level; and

an electrode lead or a multiple electrode array;

in which the pulse generator applies the electrical stimulation to the electrode lead or multiple electrode array; and

in which the electrode lead or multiple electrode array comprises an electrode to apply the electrical stimulation configured to stimulate C-afferent sensory nerve fibers innervating pancreatic beta cells in a subject, in which said electrical stimulation has a frequency of 60 Hz to 10,000 Hz and is configured to inhibit a secretion of from said C-afferent sensory nerve fibers.

38. The apparatus of claim 37 in which the electrode lead or multiple electrode array is configured for positioning at or near a dorsal root ganglion, splenic nerve, or dorsal column.

39. The apparatus of claim 37 in which the pulse generator is implantable in the subject.

40. The apparatus of claim 37 in which the apparatus further comprises a radio frequency antenna for receiving incoming signals from an external programmer.

41. The apparatus of claim 37 in which the biomarker is any one or more of insulin, glucose, calcitonin gene-related peptide, abdominal skin blood flow, abdominal skin temperature and abdominal muscle electrical activity.